title: Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.
abstract: Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period. Next, the combination was given to 129 subjects and three factors; Emotion, Somatic, and Impaired Cognition, with eigenvalues greater than one were extracted for baseline CASS-Revised (CASS-R) variables. Paired sample t-tests for pre and post-treatment scales showed significant declines (p = .00001) from pre- to post-treatment: t = 19.1 for Emotion, t = 16.1 for Somatic, and t = 14.9 for Impaired Cognition. In a two-year follow-up of 23 subjects who underwent KB220IV therapy (at least five IV treatments over seven days) plus orals for 30+ days: 21 (91%) were sober at six months, 19 (82%) having no relapse; 19 (82%) were sober at one year, 18 (78%) having no relapse; and 21 (91%) were sober two-years post-treatment, 16(70%) having no relapse. We await additional research and advise caution in interpreting these encouraging results.
authors: AminoStream, Inc., Indianapolis, IN, USA.
authors: Merlene
authors: M
authors: Miller
authors: Amanda L C
authors: AL
authors: Chen
authors: Stan D
authors: SD
authors: Stokes
authors: Susan
authors: S
authors: Silverman
authors: Abdalla
authors: A
authors: Bowirrat
authors: Matthew
authors: M
authors: Manka
authors: Debra
authors: D
authors: Manka
authors: David K
authors: DK
authors: Miller
authors: Kenneth
authors: K
authors: Perrine
authors: Thomas J H
authors: TJ
authors: Chen
authors: John A
authors: JA
authors: Bailey
authors: William
authors: W
authors: Downs
authors: Roger L
authors: RL
authors: Waite
authors: Margaret A
authors: MA
authors: Madigan
authors: Eric R
authors: ER
authors: Braverman
authors: Uma
authors: U
authors: Damle
authors: Mallory
authors: M
authors: Kerner
authors: John
authors: J
authors: Giordano
authors: Siobhan
authors: S
authors: Morse
authors: Marlene
authors: M
authors: Oscar-Berman
authors: Debmalya
authors: D
authors: Barh
authors: Kenneth
authors: K
authors: Blum
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D001519:Behavior / Q000187:drug effects*; D002908:Chronic Disease; D003071:Cognition / Q000187:drug effects; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004644:Emotions / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010865:Pilot Projects; D012008:Recurrence; D012201:Reward; D016320:Substance Abuse Treatment Centers; D013375:Substance Withdrawal Syndrome / Q000523:psychology; D019966:Substance-Related Disorders / Q000534:rehabilitation*
chemical_list: D000596:Amino Acids; D018491:Dopamine Agonists